A Study of TAK-861 for the Treatment of Narcolepsy Type 1
Public ClinicalTrials.gov record NCT06470828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to learn how effective TAK-861 (oveporexton) is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 (oveporexton) is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 (oveporexton) has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861 (oveporexton).
Study identification
- NCT ID
- NCT06470828
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2024 (Actual)
- Primary completion
- Jun 3, 2025 (Actual)
- Completion
- Jun 3, 2025 (Actual)
- Last update posted
- Aug 31, 2026
2024 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Takeda Site 48 | Phoenix | Arizona | 85054 | — |
| Takeda Site 39 | Redwood City | California | 94063 | — |
| Takeda Site 31 | Santa Ana | California | 92705 | — |
| Takeda Site 18 | Upland | California | 91786 | — |
| Takeda Site 4 | Orlando | Florida | 32803 | — |
| Takeda Site 3 | Atlanta | Georgia | 30328 | — |
| Takeda Site 45 | Boston | Massachusetts | 02115 | — |
| Takeda Site 5 | St Louis | Missouri | 63123 | — |
| Takeda Site 2 | Denver | North Carolina | 28037 | — |
| Takeda Site 6 | Cincinnati | Ohio | 45227 | — |
| Takeda Site 42 | Cleveland | Ohio | 44195 | — |
| Takeda Site 49 | Danville | Pennsylvania | 17821 | — |
| Takeda Site 1 | Columbia | South Carolina | 29201 | — |
| Takeda Site 44 | Dallas | Texas | 75231 | — |
| Takeda Site 10 | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06470828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06470828 live on ClinicalTrials.gov.